Cigarette smoking behaviors and beliefs in persons living with hepatitis C

Jonathan Shuter, Alain H. Litwin, Mark S. Sulkowski, Addi Feinstein, Avram Bursky-Tammam, Stephen Maslak, Andrea H. Weinberger, Hannah Esan, Kate S. Segal, Brianna L. Norton

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background and Rationale:: Tobacco use is common among persons living with hepatitis C (PLHC), yet little is known about their smoking behaviors and beliefs. Modern hepatitis C treatment offers a unique opportunity to intensively engage this population about other health risks, including smoking. Main Results:: Seventy-seven tobacco users (40 hepatitis C virus [HCV] seropositive and 37 HCV seronegative) enrolled in an interview study in a New York City clinic. The mean age was 51.6, 57.1% were male, 40.3% Latino, and 49.4% black. 67.5% were single and 18.2% were employed. HCV+ smokers differed from HCV- smokers in having a higher prevalence of illicit substance use, depression, and hypertension. PLHC smokers were highly motivated to quit, with 52.5% stating an intention to quit within 30 days. Most of the PLHC smokers had used cessation-directed pharmacotherapy, but almost none had tried a quitline or a quit smoking website. PLHC smokers scored higher on the intrapersonal locus of control subscale. Almost a quarter (22.5%) believed that smoking "helped fight the HCV." Conclusions:: PLHC smokers have a high burden of psychiatric and substance use comorbidity. They exhibit characteristics that distinguish them from uninfected smokers, and many harbor false beliefs about imagined benefits of smoking. They are highly motivated to quit but underutilize cessation aids. Without aggressive intervention, smoking-related morbidity will likely mute the health benefits and longevity gains associated with hepatitis C treatment. Research such as this may prove useful in guiding the development of future tobacco treatment strategies. Implications:: This is the first paper to examine, in detail, sociobehavioral correlates of tobacco use in PLHC. PLHC are recognized by the Department of Health and Human Services as a high-priority health disparities population. We are not aware of any tobacco treatment services designed specifically for PLHC. The first step in designing an intervention is defining the characteristics of the target group. Our findings will begin to address this need, and may prove useful in optimizing tobacco treatment strategies for smokers living with hepatitis C.

Original languageEnglish (US)
Pages (from-to)836-844
Number of pages9
JournalNicotine and Tobacco Research
Volume19
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Hepatitis C
Smoking
Hepacivirus
Tobacco
Tobacco Use
United States Dept. of Health and Human Services
Therapeutics
Health Priorities
Internal-External Control
Insurance Benefits
Hispanic Americans
Population
Psychiatry
Comorbidity
Interviews
Depression
Hypertension
Morbidity
Drug Therapy

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Cigarette smoking behaviors and beliefs in persons living with hepatitis C. / Shuter, Jonathan; Litwin, Alain H.; Sulkowski, Mark S.; Feinstein, Addi; Bursky-Tammam, Avram; Maslak, Stephen; Weinberger, Andrea H.; Esan, Hannah; Segal, Kate S.; Norton, Brianna L.

In: Nicotine and Tobacco Research, Vol. 19, No. 7, 01.07.2017, p. 836-844.

Research output: Contribution to journalArticle

Shuter, J, Litwin, AH, Sulkowski, MS, Feinstein, A, Bursky-Tammam, A, Maslak, S, Weinberger, AH, Esan, H, Segal, KS & Norton, BL 2017, 'Cigarette smoking behaviors and beliefs in persons living with hepatitis C', Nicotine and Tobacco Research, vol. 19, no. 7, pp. 836-844. https://doi.org/10.1093/ntr/ntw212
Shuter J, Litwin AH, Sulkowski MS, Feinstein A, Bursky-Tammam A, Maslak S et al. Cigarette smoking behaviors and beliefs in persons living with hepatitis C. Nicotine and Tobacco Research. 2017 Jul 1;19(7):836-844. https://doi.org/10.1093/ntr/ntw212
Shuter, Jonathan ; Litwin, Alain H. ; Sulkowski, Mark S. ; Feinstein, Addi ; Bursky-Tammam, Avram ; Maslak, Stephen ; Weinberger, Andrea H. ; Esan, Hannah ; Segal, Kate S. ; Norton, Brianna L. / Cigarette smoking behaviors and beliefs in persons living with hepatitis C. In: Nicotine and Tobacco Research. 2017 ; Vol. 19, No. 7. pp. 836-844.
@article{a774e065ce424f0483ebcd66aa3d0e7c,
title = "Cigarette smoking behaviors and beliefs in persons living with hepatitis C",
abstract = "Background and Rationale:: Tobacco use is common among persons living with hepatitis C (PLHC), yet little is known about their smoking behaviors and beliefs. Modern hepatitis C treatment offers a unique opportunity to intensively engage this population about other health risks, including smoking. Main Results:: Seventy-seven tobacco users (40 hepatitis C virus [HCV] seropositive and 37 HCV seronegative) enrolled in an interview study in a New York City clinic. The mean age was 51.6, 57.1{\%} were male, 40.3{\%} Latino, and 49.4{\%} black. 67.5{\%} were single and 18.2{\%} were employed. HCV+ smokers differed from HCV- smokers in having a higher prevalence of illicit substance use, depression, and hypertension. PLHC smokers were highly motivated to quit, with 52.5{\%} stating an intention to quit within 30 days. Most of the PLHC smokers had used cessation-directed pharmacotherapy, but almost none had tried a quitline or a quit smoking website. PLHC smokers scored higher on the intrapersonal locus of control subscale. Almost a quarter (22.5{\%}) believed that smoking {"}helped fight the HCV.{"} Conclusions:: PLHC smokers have a high burden of psychiatric and substance use comorbidity. They exhibit characteristics that distinguish them from uninfected smokers, and many harbor false beliefs about imagined benefits of smoking. They are highly motivated to quit but underutilize cessation aids. Without aggressive intervention, smoking-related morbidity will likely mute the health benefits and longevity gains associated with hepatitis C treatment. Research such as this may prove useful in guiding the development of future tobacco treatment strategies. Implications:: This is the first paper to examine, in detail, sociobehavioral correlates of tobacco use in PLHC. PLHC are recognized by the Department of Health and Human Services as a high-priority health disparities population. We are not aware of any tobacco treatment services designed specifically for PLHC. The first step in designing an intervention is defining the characteristics of the target group. Our findings will begin to address this need, and may prove useful in optimizing tobacco treatment strategies for smokers living with hepatitis C.",
author = "Jonathan Shuter and Litwin, {Alain H.} and Sulkowski, {Mark S.} and Addi Feinstein and Avram Bursky-Tammam and Stephen Maslak and Weinberger, {Andrea H.} and Hannah Esan and Segal, {Kate S.} and Norton, {Brianna L.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1093/ntr/ntw212",
language = "English (US)",
volume = "19",
pages = "836--844",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Cigarette smoking behaviors and beliefs in persons living with hepatitis C

AU - Shuter, Jonathan

AU - Litwin, Alain H.

AU - Sulkowski, Mark S.

AU - Feinstein, Addi

AU - Bursky-Tammam, Avram

AU - Maslak, Stephen

AU - Weinberger, Andrea H.

AU - Esan, Hannah

AU - Segal, Kate S.

AU - Norton, Brianna L.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background and Rationale:: Tobacco use is common among persons living with hepatitis C (PLHC), yet little is known about their smoking behaviors and beliefs. Modern hepatitis C treatment offers a unique opportunity to intensively engage this population about other health risks, including smoking. Main Results:: Seventy-seven tobacco users (40 hepatitis C virus [HCV] seropositive and 37 HCV seronegative) enrolled in an interview study in a New York City clinic. The mean age was 51.6, 57.1% were male, 40.3% Latino, and 49.4% black. 67.5% were single and 18.2% were employed. HCV+ smokers differed from HCV- smokers in having a higher prevalence of illicit substance use, depression, and hypertension. PLHC smokers were highly motivated to quit, with 52.5% stating an intention to quit within 30 days. Most of the PLHC smokers had used cessation-directed pharmacotherapy, but almost none had tried a quitline or a quit smoking website. PLHC smokers scored higher on the intrapersonal locus of control subscale. Almost a quarter (22.5%) believed that smoking "helped fight the HCV." Conclusions:: PLHC smokers have a high burden of psychiatric and substance use comorbidity. They exhibit characteristics that distinguish them from uninfected smokers, and many harbor false beliefs about imagined benefits of smoking. They are highly motivated to quit but underutilize cessation aids. Without aggressive intervention, smoking-related morbidity will likely mute the health benefits and longevity gains associated with hepatitis C treatment. Research such as this may prove useful in guiding the development of future tobacco treatment strategies. Implications:: This is the first paper to examine, in detail, sociobehavioral correlates of tobacco use in PLHC. PLHC are recognized by the Department of Health and Human Services as a high-priority health disparities population. We are not aware of any tobacco treatment services designed specifically for PLHC. The first step in designing an intervention is defining the characteristics of the target group. Our findings will begin to address this need, and may prove useful in optimizing tobacco treatment strategies for smokers living with hepatitis C.

AB - Background and Rationale:: Tobacco use is common among persons living with hepatitis C (PLHC), yet little is known about their smoking behaviors and beliefs. Modern hepatitis C treatment offers a unique opportunity to intensively engage this population about other health risks, including smoking. Main Results:: Seventy-seven tobacco users (40 hepatitis C virus [HCV] seropositive and 37 HCV seronegative) enrolled in an interview study in a New York City clinic. The mean age was 51.6, 57.1% were male, 40.3% Latino, and 49.4% black. 67.5% were single and 18.2% were employed. HCV+ smokers differed from HCV- smokers in having a higher prevalence of illicit substance use, depression, and hypertension. PLHC smokers were highly motivated to quit, with 52.5% stating an intention to quit within 30 days. Most of the PLHC smokers had used cessation-directed pharmacotherapy, but almost none had tried a quitline or a quit smoking website. PLHC smokers scored higher on the intrapersonal locus of control subscale. Almost a quarter (22.5%) believed that smoking "helped fight the HCV." Conclusions:: PLHC smokers have a high burden of psychiatric and substance use comorbidity. They exhibit characteristics that distinguish them from uninfected smokers, and many harbor false beliefs about imagined benefits of smoking. They are highly motivated to quit but underutilize cessation aids. Without aggressive intervention, smoking-related morbidity will likely mute the health benefits and longevity gains associated with hepatitis C treatment. Research such as this may prove useful in guiding the development of future tobacco treatment strategies. Implications:: This is the first paper to examine, in detail, sociobehavioral correlates of tobacco use in PLHC. PLHC are recognized by the Department of Health and Human Services as a high-priority health disparities population. We are not aware of any tobacco treatment services designed specifically for PLHC. The first step in designing an intervention is defining the characteristics of the target group. Our findings will begin to address this need, and may prove useful in optimizing tobacco treatment strategies for smokers living with hepatitis C.

UR - http://www.scopus.com/inward/record.url?scp=85021724281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021724281&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntw212

DO - 10.1093/ntr/ntw212

M3 - Article

C2 - 27613890

AN - SCOPUS:85021724281

VL - 19

SP - 836

EP - 844

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 7

ER -